RKER-012, a modified ActRIIB-Fc ligand trap with BMP sparing properties, attenuates pathological features of experimental pulmonary arterial hypertension - Poll - MDSpire

RKER-012, a modified ActRIIB-Fc ligand trap with BMP sparing properties, attenuates pathological features of experimental pulmonary arterial hypertension

  • By

  • R. Keith Babbs

  • Jeanne Ishimwe

  • Chris Materna

  • ffolliott M. Fisher

  • Tandicka Nurse

  • Cynthia Pinkus

  • Pritesh Jain

  • Kevin Dagbay

  • Rosa Grenha

  • Tyler Daman

  • Claire C. Tseng

  • Emily A. Ledoux

  • Evan Lema

  • Alana Gudelsky

  • Francis Wolenski

  • Harveen D. Natarajan

  • Lorena Lerner

  • Jennifer L. Lachey

  • Jasbir Seehra

  • Sachindra R. Joshi

  • June 24, 2026

  • 0 min

Share

Original Source(s)

RKER-012, a modified ActRIIB-Fc ligand trap with BMP sparing properties, attenuates pathological features of experimental pulmonary arterial hypertension

  • by R. Keith Babbs, Jeanne Ishimwe, Chris Materna, ffolliott M. Fisher, Tandicka Nurse, Cynthia Pinkus, Pritesh Jain, Kevin Dagbay, Rosa Grenha, Tyler Daman, Claire C. Tseng, Emily A. Ledoux, Evan Lema, Alana Gudelsky, Francis Wolenski, Harveen D. Natarajan, Lorena Lerner, Jennifer L. Lachey, Jasbir Seehra, Sachindra R. Joshi

  • June 24, 2026

Related Content

Ticagrelor plasma concentration, metabolite ratio, and LDH level as independent risk factors for ticagrelor-induced dyspnea in ACS patients

FDA Cites Manufacturing Issues for Cytisinicline

Application supported by Phase 3 smoking-cessation data and long-term safety findings.

Metastatic progression and treatment challenges in EBV-associated pulmonary lymphoepithelioma-like carcinoma: a case report